Q2 FY2026 · ended Jul 4, 2026 · Revenue $223.27M, -5.3% YoY · Filed Aug 13, 2026
Usana Health Sciences, Inc. (USNA) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q2 of fiscal 2026, the quarter ended Jul 4, 2026, it reported revenue of $223.3 million and a net loss of $21.4 million. Free cash flow was $20.2 million.
Revenue
$223.27M
-5.3% vs year-ago quarter
Net income
$-21.38M
-321.5% vs year-ago quarter
Operating cash flow
$23.32M
+90.9% vs year-ago quarter
Free cash flow
$20.16M
+180.4% vs year-ago quarter
EPS
$-1.16
-323.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
18.48M
+1.1% vs year-ago quarter
Net cash
$140.42M
Q4 FY2025
Operating margin
-0.1%
TTM
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- USNA (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- UT
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 896264
- Former names
- USANA INC (until Apr 27, 2000)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jul 4, 2026 |
Q1 FY2026 Apr 4, 2026 |
Q4 FY2025 Jan 3, 2026 |
Q3 FY2025 Sep 27, 2025 |
Q2 FY2025 Jun 28, 2025 |
|---|---|---|---|---|---|
| Revenue | $223.3M | $250.2M | $226.2M | $213.7M | $235.8M |
| Operating income | -$20.0M | $13.9M | $3.8M | $1.2M | $16.7M |
| Net income | -$21.4M | $7.5M | -$1.8M | -$6.5M | $9.7M |
| Diluted EPS | -$1.16 | $0.41 | -$0.10 | -$0.36 | $0.52 |
| Operating cash flow | $23.3M | $9.8M | -$3.4M | -$2.0M | $12.2M |
| Free cash flow | $20.2M | $7.1M | -$6.2M | -$5.2M | $7.2M |
| Total assets | $703.2M | $739.0M | $742.9M | $726.6M | $734.5M |
| Total liabilities | $132.2M | $144.2M | $156.6M | $145.0M | $149.0M |
| Stockholders' equity | $526.3M | $543.5M | $533.1M | $528.1M | $531.1M |
| Cash and investments | $168.6M | $162.8M | $158.4M | $145.3M | $151.3M |
| Total debt | — | — | $18.0M | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Oct 5, 2026 | Oct 5, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jul 4, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 20, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Apr 4, 2026 |
All 1001 Usana Health Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.